Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jeffm34on Apr 27, 2021 6:10pm
83 Views
Post# 33079359

RE:Why?

RE:Why?

Early on Egrifta had a perception of being a "cosmetic" drug to help reduce belly fat.  Some of that perception may still persist.  It's up to TH to sell the other benefits to physicians.  Some physicians may be reluctant to prescribe based on cost/benefit if they don't see the whole picture. More importantly I think TH needs to do a lot of direct to patient marketing as well.  Sell the patients on the long term benefits and they will be asking their physicians to prescribe it. 


palinc2000 wrote:

Knowing what we know from a lot of studies in the last year on the high incidence of Nash on people with Hiv Why dont doctors prescribe Egrifta to ALL    Patients suffering from Lipo?Can FDA make such reccomandation?



<< Previous
Bullboard Posts
Next >>